Novartis: positive results in liver cancer

(CercleFinance.com) - BeiGene on Tuesday reported positive results from a Phase 3 clinical trial of tislelizumab, a drug that may be distributed by Novartis, in liver cancer.


According to the findings, tislelizumab met its primary endpoint of being non-inferior to Bayer's sorafenib in the first-line treatment of non-operable hepatocellular carcinoma (HCC).

BeiGene states that the study included over 600 patients in the US, Europe and Asia.

For the record, BeiGene and Novartis entered into a collaboration agreement in early 2021 to jointly develop, manufacture and market tislelizumab, an anti-PD-1 antibody, in North America, Europe and Japan.


Copyright (c) 2022 CercleFinance.com. All rights reserved.